#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 28, 2017

FORTRESS BIOTECH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-35366	20-5157386
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2 Gansevoort Street, 9th Floor, New York, New York		10014
(Address of Principal Executive Offices)		(Zip Code)

Registrant's Telephone Number, Including Area Code: (781) 652-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a corporate presentation regarding Caelum Biosciences, Inc., a subsidiary of Fortress Biotech, Inc.

#### Item 9.01. Financial Statements and Exhibits.

#### (d) Exhibits

Exhibit No.	Description
99.1	Corporate presentation of Caelum Biosciences, Inc. dated February 2017.

#### SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

FORTRESS BIOTECH, INC.

Date: February 28, 2017

/s/ Lindsay A. Rosenwald

Name: Lindsay A. Rosenwald, M.D. Title: Chairman of the Board of Directors, President and Chief Executive Officer



### **Forward Looking Statements**

Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are risks relating to: results of research and development activities; uncertainties relating to preclinical and clinical testing; our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our dependence on third party suppliers; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial funds; government regulation; patent and intellectual property matters; and competition. We expressly disclaim any obligation or undertaking to update or revise any statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances after the date of this presentation.




### **About Us**






### **CAEL-101 Opportunity Overview in AL Amyloidosis**







## **Amyloid Fibrils Formation in Tissue**



### AL Amyloidosis Impact on Organs & Tissue





### **CAEL-101 Summary**






## **Specificity of Antibody Binding**



# Amyloidomas Dissolved in CAEL-101 Treated Mice With Human AL and $\kappa$



### CAEL-101 Phase 1a/1b Organ Response Rates



## Marked and Sustained Cardiac Response After a Single Dose

Cardiac response (NT-proBNP) in a patient during Phase 1a/b clinical trial of CAEL-101 antibody



#### PATIENTS PROFILE


- Refractory \u03c0 AL Amyloidosis
- Baseline NT-proBNP approx. 13,000 ng/L
- Previous treatments: 1
- Best Hematologic response to chemotherapy: VGPR
- No Organ response to chemotherapy
- Persistently elevated NT-proBNP
- ✤ NYHA Class III

#### Organ response to 11-1F4

- NYHA Class I
- NT-proBNP Reduction to below 4,000 ng/L



### **Marked and Sustained Renal Response After a Single Dose**



- ♦ Refractory \u03b1 AL Amyloidosis
- Baseline 24-hr urine protein in mg/24hr: approx. 10,000
- Previous treatments: 6
- No Organ response to chemotherapy
- Persistence of significant proteinuria

#### Organ response to GAEL-101

24 hour urine protein in ng/24 hr. approx. 3,000



### **CAEL-101 Highlights**



- Pioneering antibody
- Promising Phase 1a/1b data
  - No dose limiting toxicity
  - Marked and sustained responses even after a single dose
  - Organ activity independent of light chain sub-type
- Phase 2 to commence in 2018
- Experienced Leadership Team



### **Key Leadership**

